As of 2025-06-02, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -12.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 8,308.21 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -668.13 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 10.1x | 9.0x |
| Forward P/E multiples | 9.6x - 13.8x | 11.6x |
| Fair Price | (43.14) - (45.11) | (45.66) |
| Upside | -226.0% - -231.7% | -233.3% |
| Date | EV/EBITDA |
| 2025-05-30 | -12.44 |
| 2025-05-29 | -12.18 |
| 2025-05-28 | -11.87 |
| 2025-05-27 | -12.11 |
| 2025-05-23 | -12.18 |
| 2025-05-22 | -12.07 |
| 2025-05-21 | -12.03 |
| 2025-05-20 | -12.28 |
| 2025-05-19 | -12.28 |
| 2025-05-16 | -12.32 |
| 2025-05-15 | -12.29 |
| 2025-05-14 | -12.27 |
| 2025-05-13 | -12.15 |
| 2025-05-12 | -12.84 |
| 2025-05-09 | -12.41 |
| 2025-05-08 | -12.61 |
| 2025-05-07 | -12.88 |
| 2025-05-06 | -13.20 |
| 2025-05-05 | -13.56 |
| 2025-05-02 | -13.66 |
| 2025-05-01 | -13.61 |
| 2025-04-30 | -13.60 |
| 2025-04-29 | -13.05 |
| 2025-04-28 | -12.90 |
| 2025-04-25 | -13.02 |
| 2025-04-24 | -12.92 |
| 2025-04-23 | -12.71 |
| 2025-04-22 | -12.42 |
| 2025-04-21 | -12.22 |
| 2025-04-17 | -12.33 |
| 2025-04-16 | -12.32 |
| 2025-04-15 | -12.43 |
| 2025-04-14 | -12.61 |
| 2025-04-11 | -12.34 |
| 2025-04-10 | -11.88 |
| 2025-04-09 | -12.05 |
| 2025-04-08 | -11.27 |
| 2025-04-07 | -11.42 |
| 2025-04-04 | -11.62 |
| 2025-04-03 | -12.38 |
| 2025-04-02 | -12.54 |
| 2025-04-01 | -12.09 |
| 2025-03-31 | -12.53 |
| 2025-03-28 | -12.68 |
| 2025-03-27 | -13.05 |
| 2025-03-26 | -12.96 |
| 2025-03-25 | -13.14 |
| 2025-03-24 | -13.28 |
| 2025-03-21 | -12.58 |
| 2025-03-20 | -12.34 |